Examining Roche’s Deal to Acquire PathAI

Larger biopharma players are not outpacing independent digital pathology vendors

CEO SUMMARY: At first glance, Roche’s announcement that it had bought digital pathology and AI firm PathAI could be seen as a narrowing of options for clinical laboratories and pathology practices. However, insider Lisa-Jean Clifford says labs have long had access to digital pathology integration features that Roche touted, making the context of the PathAI […]

To access this post, you must purchase The Dark Report.

Examining Roche’s Deal to Acquire PathAI

Larger biopharma players are not outpacing independent digital pathology vendors

Comments

TABLE OF CONTENTS

Need A Group Membership? Company Discounts are Available!

You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

You have read 0 of 1 of your complimentary articles this month